16
Apr

In this week’s EuroBiotech Report, OrbiMed Advisors is in the early stages of preparing a second Israel-focused fund that could transfer $250 million (€235 million) from the pockets of investors into the bank accounts of local life science players. And more.

…read more

Source: Israel awaits $250M fund, ThromboGenics spins out oncology asset, MolMed licenses CAR-T

    

0 No comments